BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K. 1999

K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19246, USA.

The structure-based design and synthesis of lactam-constrained azapeptide inhibitors of human cathepsin K are described. Enhanced stability to proteolytic cleavage over acyclic analogues is discussed.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010010 Osteoclasts A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption. Odontoclasts,Cementoclast,Cementoclasts,Odontoclast,Osteoclast
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011760 Pyrrolidinones A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed) Pyrrolidinone,Pyrrolidone,Pyrrolidones
D002403 Cathepsins A group of lysosomal proteinases or endopeptidases found in aqueous extracts of a variety of animal tissues. They function optimally within an acidic pH range. The cathepsins occur as a variety of enzyme subtypes including SERINE PROTEASES; ASPARTIC PROTEINASES; and CYSTEINE PROTEASES. Cathepsin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000588 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015853 Cysteine Proteinase Inhibitors Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. Acid Cysteine Proteinase Inhibitor,Cysteine Protease Inhibitor,Cysteine Protease Inhibitors,Cysteine Proteinase Antagonist,Cysteine Proteinase Antagonists,Cysteine Proteinase Inhibitor,Cysteine Proteinase Inhibitors, Endogenous,Cysteine Proteinase Inhibitors, Exogenous,alpha-Cysteine Protease Inhibitor,Acid Cysteine Proteinase Inhibitors,alpha-Cysteine Protease Inhibitors,Antagonist, Cysteine Proteinase,Antagonists, Cysteine Proteinase,Inhibitor, Cysteine Protease,Inhibitor, Cysteine Proteinase,Inhibitor, alpha-Cysteine Protease,Inhibitors, Cysteine Protease,Inhibitors, Cysteine Proteinase,Inhibitors, alpha-Cysteine Protease,Protease Inhibitor, Cysteine,Protease Inhibitor, alpha-Cysteine,Protease Inhibitors, Cysteine,Protease Inhibitors, alpha-Cysteine,Proteinase Antagonist, Cysteine,Proteinase Antagonists, Cysteine,Proteinase Inhibitor, Cysteine,Proteinase Inhibitors, Cysteine,alpha Cysteine Protease Inhibitor,alpha Cysteine Protease Inhibitors

Related Publications

K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Cathepsin K and the design of inhibitors of cathepsin K.
January 2000, Current pharmaceutical design,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.
August 2006, Bioorganic & medicinal chemistry letters,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Design of cathepsin K inhibitors for osteoporosis.
January 2005, Current topics in medicinal chemistry,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
March 2019, Bioorganic & medicinal chemistry,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Highly selective azadipeptide nitrile inhibitors for cathepsin K: design, synthesis and activity assays.
February 2013, Organic & biomolecular chemistry,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors.
August 2020, Bioorganic & medicinal chemistry,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Design of potent and selective human cathepsin K inhibitors that span the active site.
December 1997, Proceedings of the National Academy of Sciences of the United States of America,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Crystal structure of human osteoclast cathepsin K complex with E-64.
February 1997, Nature structural biology,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Design of small molecule ketoamide-based inhibitors of cathepsin K.
February 2004, Bioorganic & medicinal chemistry letters,
K J Duffy, and L H Ridgers, and R L DesJarlais, and T A Tomaszek, and M J Bossard, and S K Thompson, and R M Keenan, and D F Veber
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
August 2002, Current molecular medicine,
Copied contents to your clipboard!